James G. Karras

6.7k total citations · 2 hit papers
57 papers, 5.6k citations indexed

About

James G. Karras is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, James G. Karras has authored 57 papers receiving a total of 5.6k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Immunology, 26 papers in Oncology and 20 papers in Molecular Biology. Recurrent topics in James G. Karras's work include Cytokine Signaling Pathways and Interactions (23 papers), Immune Cell Function and Interaction (11 papers) and T-cell and B-cell Immunology (10 papers). James G. Karras is often cited by papers focused on Cytokine Signaling Pathways and Interactions (23 papers), Immune Cell Function and Interaction (11 papers) and T-cell and B-cell Immunology (10 papers). James G. Karras collaborates with scholars based in United States, United Kingdom and Switzerland. James G. Karras's co-authors include Richard Jove, James Turkson, Eric B. Haura, Lanxi Song, Thomas L. Rothstein, Guilian Niu, Drew M. Pardoll, Hua Yu, Kenneth L. Wright and Mei Huang and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Nature Medicine.

In The Last Decade

James G. Karras

55 papers receiving 5.5k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis

2002 1.0k citations Guilian Niu, Kenneth L. Wright et al. Oncogene profile →
Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression

2001 505 citations Pearlie K. Epling‐Burnette, Jin Hong Liu et al. Journal of Clinical Investigation profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James G. Karras United States	33	2.6k	2.5k	1.9k	953	945	57	5.6k
Osamu Miura Japan	43	3.4k 1.3×	2.7k 1.1×	2.3k 1.2×	914 1.0×	723 0.8×	243	7.4k
Elaine M. Hurt United States	35	2.4k 0.9×	3.1k 1.3×	2.0k 1.1×	457 0.5×	1.0k 1.1×	59	6.3k
Heehyoung Lee United States	24	3.0k 1.1×	3.0k 1.2×	2.1k 1.1×	717 0.8×	1.6k 1.7×	26	6.2k
Ralf Buettner United States	24	2.9k 1.1×	2.9k 1.2×	1.1k 0.6×	834 0.9×	1.1k 1.1×	63	5.6k
Grazia Ambrosini United States	27	2.2k 0.8×	4.8k 2.0×	1.2k 0.6×	414 0.4×	743 0.8×	48	6.8k
JC Reed United States	20	1.7k 0.6×	4.0k 1.6×	1.0k 0.5×	854 0.9×	630 0.7×	31	6.0k
Didier Bouscary France	40	1.4k 0.5×	3.5k 1.4×	993 0.5×	821 0.9×	623 0.7×	163	6.3k
Maciej Kujawski United States	28	2.4k 0.9×	2.3k 0.9×	2.2k 1.2×	567 0.6×	850 0.9×	60	5.1k
George Z. Rassidakis United States	43	2.4k 0.9×	2.4k 1.0×	1.1k 0.6×	1.9k 1.9×	681 0.7×	140	5.2k
Colette Adida France	21	1.8k 0.7×	3.6k 1.5×	1.0k 0.5×	391 0.4×	750 0.8×	24	5.2k

Countries citing papers authored by James G. Karras

Since Specialization

Citations

This map shows the geographic impact of James G. Karras's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James G. Karras with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James G. Karras more than expected).

Fields of papers citing papers by James G. Karras

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James G. Karras. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James G. Karras. The network helps show where James G. Karras may publish in the future.

Co-authorship network of co-authors of James G. Karras

This figure shows the co-authorship network connecting the top 25 collaborators of James G. Karras. A scholar is included among the top collaborators of James G. Karras based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James G. Karras. James G. Karras is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Karras, James G., María Marcuello, Claire T. Roberts, et al.. (2024). Preclinical Evaluation of HTX-001 as a Novel Anti-fibrotic Therapy for non-obstructive HCM. Journal of Cardiac Failure. 30. S9–S10. 1 indexed citations

Hogg, Chloe, Gregory D. Ferguson, Diane M. Hargrove, et al.. (2021). Bioluminescent imaging in induced mouse models of endometriosis reveals differences in four model variations. Disease Models & Mechanisms. 14(8). 19 indexed citations

Tan, Shyh‐Han, Ayush Dagvadorj, Feng Shen, et al.. (2008). Transcription Factor Stat5 Synergizes with Androgen Receptor in Prostate Cancer Cells. Cancer Research. 68(1). 236–248. 88 indexed citations

Ye, Sheng‐Long, Ruixia Sun, Yinkun Liu, et al.. (2006). Inhibition of Growth and Metastasis of Human Hepatocellular Carcinoma by Antisense Oligonucleotide Targeting Signal Transducer and Activator of Transcription 3. Clinical Cancer Research. 12(23). 7140–7148. 118 indexed citations

Nagy, Zsuzsanna, Hallgeir Rui, Stanislaw M. Stepkowski, James G. Karras, & Robert A. Kirken. (2006). A Preferential Role for STAT5, not Constitutively Active STAT3, in Promoting Survival of a Human Lymphoid Tumor. The Journal of Immunology. 177(8). 5032–5040. 20 indexed citations

Dokka, Sujatha, Scott Cooper, Susan Kelly, Gregory E. Hardee, & James G. Karras. (2005). Dermal Delivery of Topically Applied Oligonucleotides via Follicular Transport in Mouse Skin. Journal of Investigative Dermatology. 124(5). 971–975. 48 indexed citations

Chiarle, Roberto, William J. Simmons, Girish Dhall, et al.. (2005). Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nature Medicine. 11(6). 623–629. 349 indexed citations

Duan, Wei, Jasmine H.P. Chan, Jeffrey R. Crosby, et al.. (2004). Inhaled p38α Mitogen-activated Protein Kinase Antisense Oligonucleotide Attenuates Asthma in Mice. American Journal of Respiratory and Critical Care Medicine. 171(6). 571–578. 129 indexed citations

Kirkiles-Smith, Nancy C., Keyvan Mahboubi, Janet Plescia, et al.. (2004). IL-11 Protects Human Microvascular Endothelium from Alloinjury In Vivo by Induction of Survivin Expression. The Journal of Immunology. 172(3). 1391–1396. 40 indexed citations

10.

Niu, Guilian, Kenneth L. Wright, Mei Huang, et al.. (2002). Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene. 21(13). 2000–2008. 1019 indexed citations breakdown →

11.

Epling‐Burnette, Pearlie K., Jin Hong Liu, Robyn Catlett-Falcone, et al.. (2001). Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. Journal of Clinical Investigation. 107(3). 351–362. 505 indexed citations breakdown →

12.

Karras, James G., Martin A. Maier, Tao Lü, Andrew T. Watt, & Muthiah Manoharan. (2001). Peptide Nucleic Acids Are Potent Modulators of Endogenous Pre-mRNA Splicing of the Murine Interleukin-5 Receptor-α Chain. Biochemistry. 40(26). 7853–7859. 52 indexed citations

13.

Karras, James G., Robert A. McKay, Tao Lü, Nicholas M. Dean, & Brett P. Monia. (2000). Antisense Inhibition of Membrane-Bound Human Interleukin-5 Receptor-α Chain Does Not Affect Soluble Receptor Expression and Induces Apoptosis in TF-1 Cells. Antisense and Nucleic Acid Drug Development. 10(5). 347–357. 4 indexed citations

14.

Karras, James G., Robert A. McKay, Scott Cooper, et al.. (2000). Inhibition of Antigen-Induced Eosinophilia and Late Phase Airway Hyperresponsiveness by an IL-5 Antisense Oligonucleotide in Mouse Models of Asthma. The Journal of Immunology. 164(10). 5409–5415. 55 indexed citations

15.

Karras, James G., et al.. (1997). Induction of STAT protein signaling through the CD40 receptor in B lymphocytes: distinct STAT activation following surface Ig and CD40 receptor engagement. The Journal of Immunology. 159(9). 4350–4355. 62 indexed citations

16.

Wang, Zihua, et al.. (1997). Unmethylated CpG Motifs Protect Murine B Lymphocytes against Fas-Mediated Apoptosis. Cellular Immunology. 180(2). 162–167. 30 indexed citations

17.

Karras, James G., J A Ledbetter, Gary L. Schieven, et al.. (1996). Molecular Mechanisms of Toxicant-Induced Immunosuppression: Role of Second Messengers. The Annual Review of Pharmacology and Toxicology. 36(1). 131–159. 38 indexed citations

18.

Karras, James G. & Michael P. Holsapple. (1994). Inhibition of Calcium-Dependent B Cell Activation by 2,3,7,8-Tetrachlorodibenzo-p-dioxin. Toxicology and Applied Pharmacology. 125(2). 264–270. 13 indexed citations

19.

Morris, Dale L., James G. Karras, & Michael P. Holsapple. (1993). Direct effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on responses to lipopolysaccharide (LPS) by isolated murine B-cells. Immunopharmacology. 26(2). 105–112. 25 indexed citations

20.

Fong, Sherman, et al.. (1984). Delineation of a cross-reactive idiotype on human autoantibodies with antibody against a synthetic peptide.. The Journal of Experimental Medicine. 159(5). 1502–1511. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact